Special Issue "Neuroprotective Strategies 2019"
Deadline for manuscript submissions: 31 December 2019
Prof. Dr. Katalin Prokai-Tatrai
Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA
Website | E-Mail
Interests: drug design of central nervous system agents; neuropeptides and peptidomimetics; prodrugs for CNS delivery; CNS-selective estrogen therapy; neuroprotection; proteomics
It has been 10 years since we started the “Neuroprotective Strategies” collection, offering the latest information on neuroprotection through the preclinical/basic science assessments of the various in vitro and animal models relevant to neurodegeneration, drug discovery efforts, and clinical case reports. We hope that this Special Issue will continue to provide a forum for thought-provoking comments, opinions, and perspectives, in addition to traditional reviews and research articles on the latest developments of therapeutics in the field. We especially encourage submissions that address the critical issues that have prevented successful the clinical translations of otherwise promising laboratory data. These issues include the limitations of in vitro studies and preclinical animal models to mirror the multiple pathologies underlying human neurodegenerative diseases, the lack of drug-likeness of experimental agents, obstacles of drug delivery to the CNS, and the consideration of ADMET and pharmacokinetics, especially in early stage drug discovery. Critical reviews of relevant patent literature and clinical findings are also welcome. I wish to thank all of the authors for their exceptional contributions to this Special Issue over the years, and I look forward to receiving future contributions to the 10th anniversary issue on the promising and challenging aspects of neuroprotective strategies. I hope this topical collection has been, and will continue to be, a useful reference for everybody interested in the subject.
Prof. Dr. Katalin Prokai-Tatrai
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Clinical case report
- CNS-targeting drug design and drug-likeness
- Drug delivery
- In-silico drug design and disease models
- Ischemia and reperfusion
- Ocular neurodegeneration
- Oxidative stress
- Peripheral nervous system
- Spinal cord injury
- Structure–activity relationships
- Translational medicine
- Traumatic brain injury